Citation: | LI Zihuang, LI Xianming, YANG Dong, XU Gang, ZHOU Yayan, WU Shihai, LI Zhuangling. Clinical Analysis of Temozolomide Combined with Radiotherapy on High-grade Glioma[J]. Cancer Research on Prevention and Treatment, 2015, 42(02): 185-189. DOI: 10.3971/j.issn.1000-8578.2015.02.019 |
[1] |
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas, a clinical review[J]. JAMA, 2013, 310(17): 1842-50.
|
[2] |
Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009[J]. Neuro Oncol, 20 12, 14 suppl 5: v1-49.
|
[3] |
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-96.
|
[4] |
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5- year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10 (5): 459-66.
|
[5] |
Oike T, Suzuki Y, Sugawara K, et al. Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results[J]. PLoS One, 2013, 8(11): e78943.
|
[6] |
DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy[J]. J Clin Oncol, 2009, 27(35): 58 61-2.
|
[7] |
Omar AI, Mason WP. Temozolomide: the evidence for its therapeutic efficacy in malignant astrocytoma[J]. Core Evid, 2010, 4: 93-111.
|
[8] |
Dresemann G. Temozolomide in malignant glioma[J]. Onco Targets Ther, 2010, 3: 139-46.
|
[9] |
Scoccianti S, Magrini SM, Ricardi U, et al. Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology)[J]. Neuro Oncol, 2012, 14(6): 798-807.
|
[10] |
Zhang L, Wu X, Xu T, et al. Chemotherapy plus radiotherapy versus radiotherapy alone in patients with anaplastic glioma: a systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 20 13,139(5): 719-26.
|
[11] |
Gutenberg A, Bock HC, Reifenberger G, et al. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis[J]. Acta Neurochir(Wien), 2013, 155(3): 429-35.
|
[12] |
Valduvieco I, Verger E, Bruna J, et al. Impact of radiotherapy delay on survival in glioblastoma[J]. Clin Transl Oncol, 2013, 15 (4): 278-82.
|
[13] |
Chen YD, Feng J, Fang T, et al. Effect of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy on clinical outcomes in patients with glioblastoma multiforme[J]. Chin Med J(Engl), 2013, 126 (12): 2320-4.
|
[14] |
Roldán Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme[J]. J Neurooncol, 2012, 108(1): 173-7.
|
[15] |
Seiz M, Krafft U, Freyschlag CF, et al. Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution[J]. J Cancer Res Clin Oncol, 2010, 136(11): 1691-5.
|